Overview

Extending adjuvant therapy beyond the standard course targets the residual risk that drives late HER2-positive relapse. Neratinib (Hernix) 40 mg tablets are used for up to one year of extended adjuvant treatment in early HER2-positive breast cancer after trastuzumab-based therapy. The eligible population is defined not by metastatic spread but by stage and prior completion of standard adjuvant care. For B2B buyers this creates a predictable, time-bound cohort of early-stage patients. We help distributors plan around the fixed one-year course that defines demand.

How It Works

Neratinib is an irreversible tyrosine-kinase inhibitor of the HER2, HER4, and EGFR pathways, providing a sustained blockade distinct from the periodic antibody used earlier. By continuing anti-HER2 pressure through the extended adjuvant window, it aims to suppress micrometastatic clones before they establish. The clinical population is therefore early-stage and node-involved rather than metastatic. From a procurement standpoint the demand signal is the number of patients finishing standard adjuvant therapy and starting the extended course. Distributors should forecast from that transition volume.

Indications

The 40 mg tablet is indicated for extended adjuvant treatment of early HER2-positive breast cancer, typically initiated after completion of trastuzumab-based adjuvant therapy. Eligibility follows stage and prior-treatment history per the local label. Importers must verify the licensed indication and any contraindications in each market. We supply the listed 180-tablet pack sized to the once-daily, one-year regimen.

Dosage & Administration

Neratinib is taken as 240 mg once daily, which the presented 40 mg tablet supports as six tablets per day, continued for twelve months. Tablets should be swallowed whole and stored in the original container with desiccant. Because the course is fixed at one year, procurement can forecast total treatment cycles with unusual precision. We recommend confirming the expected patient cohort before a bulk commitment.

Storage & Sourcing

Store the tablets at 2-8°C and protect them from moisture during handling. Our export process uses temperature-controlled packaging with documented transit logging. Lead times and minimum order quantities are agreed per destination and registration status. Each delivery carries the batch-release certificate appropriate for customs and pharmacy release.

FAQ

Q: Who qualifies for the extended adjuvant course? Early-stage, HER2-positive patients who have completed standard trastuzumab-based adjuvant therapy, per the local label.

Q: Why is the treatment duration fixed at one year? The extended adjuvant benefit is defined by a twelve-month course, which also makes demand forecasting highly predictable.

Q: What prophylaxis should distributors communicate? Antidiarrheal prophylaxis, commonly loperamide, is recommended at initiation to manage the main manageable side effect.

Q: Is cardiac monitoring part of the plan? Baseline and periodic cardiac assessment is advised, consistent with anti-HER2 therapy guidance.